Uk cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2639-2650

  Kielhorn, Adrian ^a   Porter, Duncan ^b   Diamantopoulos, Alexander ^c   Lewis, Gavin ^d  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c IQVIA   (United States)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Cost effectiveness; Health economics; QALY; Rheumatoid arthritis; Rituximab; Utility

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LIFESPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POPULATION RESEARCH; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHEUMATOID ARTHRITIS; UNITED KINGDOM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 53349109121     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802321683     Document Type: Article

References (55)

1. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23:S43-52
2. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45
3. Felson DT, Anderson JJ Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
4. Weirblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45
5. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
6. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9
7. Van Vollenhoven RF, Carli CC, Bratt J, et al. Six year report of the STURE registry for biologicals in rheumatology: satisfactory overall results but plenty room for improvement. Arthritis Rheum 2005;52 (Suppl 9):Poster no. 273
8. Spanish Society of Rheumatology. BIOBADASER Annual Report 2005. Spanish registry for adverse events of biological therapies in rheumatic diseases. 2005
9. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28-33
10. Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401
11. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806
12. Kielhorn A, Bombardieri C, Aultman R, et al. Rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study Ann Rheum Dis 2006;65(Suppl II):324
13. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. April 2004. Available from http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf [Last accessed 14 July 2008]
14. Scottish Medicines Consortium. Guidance to manufacturers for completion of New Products Assessment form. 2005 (Revised 2007). Available from http://209.85.215.104/ search?q=cache:4bldwen]IyQJ:www.scottishmedicines.org.uk/smc/files/ New%2520Product%252OAssessment%252OForm%2520(NPAF) Guidance%252ONotesCombinedClinical%2520and%2520Economic (Master%2520updated%252OJune%252007)%2520FINAL.doc+Scottisb+Medicines+ Consortium.+Guidance+to+manufacturer%7s+for+completion+of+New+Products+ Assessment+form.+2005&hl=en&ct=clnk&cd=l&gl=us [Last accessed 14 July 2008]
15. Gabriel S, Drummond M, Maetzel A, et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90
16. National Institute for Health and Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Report No. Technology Appraisal No. 36. 2002. Available from http://www.nice.org.uk/nicemedia/pdf/RA-PDF.pdf [Last accessed 14 July 2008]
17. Hyrich KL, Silman AJ, Lunt M, et al. Influence of response and adverse event rates to a first anti-TNF alpha agent on the outcome from switching to a second agent: results from British Society of Rheumatology Biologics Register. BSR Biologics Register Newsletter [Online]. 2006. Available from http://www.boneandjointdecade.org/ ViewDocument.aspx?Contld=1720 [Last accessed 27 Jul 2007]
18. Kielhorn A, Tony H, Jost F, et al. Rituximab in rheumatoid arthritis: translating ACR responses into benefit for the patients. Ann Rheum Dis 2006;65(Suppl II):324
19. Scott DL, Garrood T. Quality of life measures: use and abuse. Baillière's Best Prac Res Clin Rheumatol 2000;14:663-87
20. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002
21. Bay-ton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technology Assessment 2004;8:iiil-91
22. Crnkic M, Teleman A, Saxne T, et al. Survival on drugs as a tool for the evaluation of drug tolerability. Initial experience in southern Sweden of infliximab, etanercept and leflunomide in reumatoid arthritis. Rheumatology (Oxford) 2001;40(Suppl 9):231
23. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11
24. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542-50
25. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technology Assessment. 2005;9:1-134, iii-iv
26. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472
27. Engels EA, Schmid CH, Terrin N, et al. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med 2000;19:1707-28
28. British National Formulary (BNF 50). 2005 [26 Oct 2005]
29. Remicade - summary of product characteristics. Available from: http://www.remicade.com [Last accessed 14 July 2008]
30. Nuijten MJ, Engelfriet P, Duijn K, et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001;19:1051-64
31. Netten A, Curtis L. Unit costs of health and social care. PSSRU (Personal Social Services Research Unit) University of Kent, UK, 2004
32. Department of Health. NHS reference cost. 2004. Available from http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_4105545 [Last accessed 14 July 2008]
33. Netten A, Curtis L. Unit costs of health and social care. PSSRU (Personal Social Services Research Unit) University of Kent, UK, 2003
34. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70
35. Kobelt G, Jonsson L, Lindgren P, et al. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-9
36. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7527 patients. Arthritis Rheum 2003;48:2750-62
37. Pugner KM, Scott DI, Holmes JW, et al. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20
38. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42:1209-18
39. Wiles N, Cooper NJ, Symmons DPM. Resource use within the Norfolk Arthritis Register (NOAR) cohort during the first five years of disease. Report for Roche. 2005
40. Kobelt G, Eberhardt K, Jonsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56
41. Kobelt G, Lindgren P, Singh A, et al. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-9
42. Netten A, Curtis L. Unit costs of health and social care. PSSRU (Personal Social Services Research Unit) University of Kent, UK, 2002
43. National Statistics. Annual survey of hours and earnings (ASHE) - 2004 results; table 1.7A: annual pay: gross, full time employees. 2004
44. The United Kingdom Government Actuary's Department. GAD, 2005
45. Kobelt G, Jonsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-35
46. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50
47. Munro R, Hampson R, McEntegart A, et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998;57:88-93
48. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:726-33
49. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. New Engl J Med 1995;333:137-41
50. Ruta DA, Hurst NP, Kind P, et al. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). B J Rheum 1998;37:425-36
51. National Institute for Health and Clinical Excellence. Rituximab for the treatment of rheumatoid arthritis. Report No. Technology Appraisal No. 126. 2007. Available at: Available from http://www.nice.org.uk/guidance/ index.isp?action=download&o= 36101 [Last accessed 30 June 2008]
52. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005; 44:157-63
53. Brennan A, Bansback N, Reynolds A, et al. Modelling the costeffectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004;43:62-72
54. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36:551-9
55. Lewis G, Porter D, Brown B, et al. Economic consequences of providing rituximab as a new therapeutic option for rheumatoid arthritis in the UK. Ann Rheum Dis 2006;65(Suppl II):283